These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33015740)

  • 81. Target identification of covalently binding drugs by activity-based protein profiling (ABPP).
    Pichler CM; Krysiak J; Breinbauer R
    Bioorg Med Chem; 2016 Aug; 24(15):3291-303. PubMed ID: 27085673
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Model-based drug discovery: implementation and impact.
    Visser SA; Aurell M; Jones RD; Schuck VJ; Egnell AC; Peters SA; Brynne L; Yates JW; Jansson-Löfmark R; Tan B; Cooke M; Barry ST; Hughes A; Bredberg U
    Drug Discov Today; 2013 Aug; 18(15-16):764-75. PubMed ID: 23726890
    [TBL] [Abstract][Full Text] [Related]  

  • 83. High-throughput hydrogen bond strength calculation and its applications in optimizing drug ADME properties.
    Shen J; Yang Y; Broughton H; Watson IA; Desai PV
    Future Med Chem; 2019 Mar; 11(6):511-524. PubMed ID: 30892942
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Covalent Docking in Drug Discovery: Scope and Limitations.
    Scarpino A; Ferenczy GG; Keserű GM
    Curr Pharm Des; 2020; 26(44):5684-5699. PubMed ID: 33155894
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Bond stability of the "undesirable" heteroatom-heteroatom molecular moieties for high-throughput screening libraries.
    Yu B; Reynisson J
    Eur J Med Chem; 2011 Dec; 46(12):5833-7. PubMed ID: 22000918
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
    Ma Y; Li L; He S; Shang C; Sun Y; Liu N; Meek TD; Wang Y; Shang L
    J Med Chem; 2019 Jul; 62(13):6146-6162. PubMed ID: 31184893
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Computational Models of Drug-target Interaction Prediction.
    Ding Y; Tang J; Guo F
    Protein Pept Lett; 2020; 27(5):348-358. PubMed ID: 30968771
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Overview of determination of biopharmaceutical properties for development candidate selection.
    Yazdanian M
    Curr Protoc Pharmacol; 2013 Mar; Chapter 9():Unit9.17. PubMed ID: 23456615
    [TBL] [Abstract][Full Text] [Related]  

  • 89. How do we optimize chemical space navigation?
    Vogt M
    Expert Opin Drug Discov; 2020 May; 15(5):523-525. PubMed ID: 32067507
    [No Abstract]   [Full Text] [Related]  

  • 90. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Modeling ADMET.
    Ghosh J; Lawless MS; Waldman M; Gombar V; Fraczkiewicz R
    Methods Mol Biol; 2016; 1425():63-83. PubMed ID: 27311462
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Externally predictive quantitative modeling of supercooled liquid vapor pressure of polychlorinated-naphthalenes through electron-correlation based quantum-mechanical descriptors.
    Vikas ; Chayawan
    Chemosphere; 2014 Jan; 95():448-54. PubMed ID: 24168755
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Late-Stage Functionalization of Drug-Like Molecules Using Diversinates.
    Kuttruff CA; Haile M; Kraml J; Tautermann CS
    ChemMedChem; 2018 May; 13(10):983-987. PubMed ID: 29534329
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel chemical space exploration via natural products.
    Rosén J; Gottfries J; Muresan S; Backlund A; Oprea TI
    J Med Chem; 2009 Apr; 52(7):1953-62. PubMed ID: 19265440
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A minimalist fragment approach for the design of natural-product-like synthetic scaffolds.
    Genis D; Kirpichenok M; Kombarov R
    Drug Discov Today; 2012 Nov; 17(21-22):1170-4. PubMed ID: 22659098
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Overview of chemical diversity.
    Triggle DJ
    Curr Protoc Pharmacol; 2001 May; Chapter 9():Unit 9.1. PubMed ID: 21971814
    [No Abstract]   [Full Text] [Related]  

  • 97. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 98. Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery.
    Meghani NM; Amin HH; Lee BJ
    Drug Discov Today; 2017 Nov; 22(11):1604-1619. PubMed ID: 28754291
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Privileged scaffolds for library design and drug discovery.
    Welsch ME; Snyder SA; Stockwell BR
    Curr Opin Chem Biol; 2010 Jun; 14(3):347-61. PubMed ID: 20303320
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Revealing atropisomer axial chirality in drug discovery.
    LaPlante SR; Edwards PJ; Fader LD; Jakalian A; Hucke O
    ChemMedChem; 2011 Mar; 6(3):505-13. PubMed ID: 21360821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.